News
-
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis -
Zedira supports Gordon Research Conference
-
Press release: Zedira announces ISO 9001:2015 certification -
Zedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay” -
Artikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch) -
Preview: Catalogue Editorial 2019 -
Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
-
Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
-
Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
-
Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
-
Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
-
Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
-
Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
-
Press release: Additional subsidy funding for clinical development of a celiac disease drug
-
Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
-
Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
-
Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
-
Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
Blog
-
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible? -
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering -
Tridegin as FXIIIa inhibitor -
Microbial transglutaminase: from discovery to market -
Tissue transglutaminase inhibitors -
Tissue transglutaminase in Alzheimer’s Disease -
Factor XIIIa: novel target for anticoagulation? -
Microbial transglutaminase for site-specific protein conjugation -
Transglutaminase antibodies in ataxia